



COMPANY RELEASE

24 September 2007

Brian Garra, M.D. appointed to AION Scientific Advisory Board

Perth, Australia - AION Diagnostics Inc, a molecular imaging company developing medical imaging agents, announced the appointment of Brian S. Garra M.D., expert in radiological device regulation, to its Scientific Advisory Board.

Dr. Garra has served as Chairman of the Food and Drug Administration's (F.D.A.) Radiological Devices Panel. A leading advocate for the use of sensor tracking in 3D ultrasound technology, Dr. Garra currently holds positions on the review panels for several journals including Radiology, American Journal of Roentgenology, Journal of Ultrasound in Medicine and Physics in Medicine & Biology. Dr. Garra has received numerous awards including the American Institute of Ultrasound in Medicine Presidential Recognition Award. He is currently Vice Chair of Research and Professor of Radiology as well as Co-Director of Ultrasound at Fletcher Allen Health Care at the University of Vermont in the United States.

"Dr. Garra's regulatory expertise will assist AION in accelerating commercialization of the Company's imaging product portfolio," reported Dr. Anna Kluczevska, President and CEO of AION.

The AION Scientific Advisory Board is chartered to provide independent scientific and strategic advice to the Company's operations.

- ENDS -

Released by:

AION Diagnostics

Alexandra Brown

Ph: +61 (8) 6461 9400

alexandra_brown@aiondiagnostics.com

European Public Relations

Dr. Eva Reuter

Ph: +49 (254) 393 0740

e.reuter@dr-reuter.eu

NOTES TO EDITORS:

AION Diagnostics (AION) is a global biotechnology company dedicated to the commercialization of medical imaging contrast and molecular imaging agents for early stage detection of critical diseases. Founded in 2004, AION secured strategic alliances with universities, research institutions and industry partners internationally.

Exploiting the 10-year history of discoveries of porous silicon made at the former UK Defence Evaluation Agency (now QinetiQ) and backed by USD\$50 million in cumulative previous investment in the technology, AION have developed modified porous silicon (mpSi™) which has been proven visible across all major imaging modalities. AION is leveraging the unique visualization capabilities of the mpSi™ technology platform with its biodegradable and biocompatible properties to produce imaging product divisions in Marking, Contrast and Molecular Imaging Agents. Additionally, one such strategic objective is the development of collaborations incorporating the mpSi™ platform with other materials to create superior versions of existing products.

Continuing to strive for better solutions to unmet diagnostic needs, AION's products are committed to the timely visualization of pathologies in a manner which may facilitate prevention rather than treatment of disease.

This press release and the information contained therein do not constitute an offer for sale or a solicitation for submission of an offer for purchase or subscription of shares in AION Diagnostics Inc in Germany nor outside Germany, especially in the United States, Canada, Japan or the United Kingdom and Northern Ireland. This press release is provided solely for information purposes.